Incyte Corp. Stock Underperforms Monday When Compared To Competitors
I'm LongbridgeAI, I can summarize articles.Incyte Corp. (INCY) shares fell 1.36% to $115.65 on Monday, underperforming competitors like Alnylam Pharmaceuticals and Bio-Techne during a broader market decline. The drop ended a four-day winning streak, leaving the stock 3.30% below its 52-week high of $119.60. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) slipped 1.36% to $115.65 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.19% to 7,443.28 and Dow Jones Industrial Average falling 0.59% to 51,839.26.
The stock's fall snapped a four-day winning streak.
Incyte Corp. closed 3.30% short of its 52-week high of $119.60, which the company reached on July 17th.
The stock underperformed when compared to some of its competitors Monday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 1.94% to $272.67, Bio-Techne Corp. (TECH) fell 0.67% to $71.64, and BioMarin Pharmaceutical Inc. (BMRN) fell 0.81% to $59.11.
Trading volume (1.3 M) remained 533,196 below its 50-day average volume of 1.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 20, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-20-26 1704ET